title: Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.
abstract: HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.
authors: From the *Program for HIV Prevention and Treatment (IRD UMI 174), Faculty of Associated Medical Sciences, Department of Medical Technology, Chiang Mai University, Chiang Mai, Thailand; †Harvard T.H Chan School of Public Health, Boston, Massachusetts; ‡National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal and Pediatric Infectious Disease Branch, Bethesda, Maryland; §Jacobi Medical Center, Bronx, New York; ¶Columbia University Medical Center, New York, New York; ‖HJF-DAIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to NIAID, NIH, DHHS, Bethesda, Maryland; **Frontier Science & Technology, Amherst, New York, New York; ††University of Alabama at Birmingham, Birmingham, Alabama; and ‡‡Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
authors: Tim R
authors: TR
authors: Cressey
authors: Rohan
authors: R
authors: Hazra
authors: Andrew
authors: A
authors: Wiznia
authors: Marc
authors: M
authors: Foca
authors: Patrick
authors: P
authors: Jean-Philippe
authors: Bobbie
authors: B
authors: Graham
authors: Jennifer R
authors: JR
authors: King
authors: Paula
authors: P
authors: Britto
authors: Vincent J
authors: VJ
authors: Carey
authors: Edward P
authors: EP
authors: Acosta
authors: Ram
authors: R
authors: Yogev
mesh_terms: D000293:Adolescent; D000328:Adult; D000069446:Atazanavir Sulfate / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002648:Child; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D000069446:Atazanavir Sulfate